Comparison of clinicopathological features and prognostic factors between advanced invasive lobular cancer and invasive ductal breast cancer
10.3781/j.issn.1000-7431.2017.33.579
- Author:
Jibo ZHANG
1
Author Information
1. Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin' S Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Clinicopathological features;
Invasive ductal carcinoma;
Invasive lobular carcinoma;
Metastasis;
Prognosis
- From:
Tumor
2017;37(11):1188-1201
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze and compare the clinicopathological features and prognostic factors between patients with advanced breast invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Methods: Fifty-nine female patients with advanced breast ILC from Tianjin Medical University Cancer Institute and Hospital were included in this retrospective case-controlled study. Matched two hundred and thirty-six female patients with advanced breast IDC were selected according to age at diagnosis and the time of surgery (±2 years) in Tianjin Medical University Cancer Institute and Hospital between January 2008 and December 2016. Clinical and pathological features and prognostic factors were analyzed by using univariate and multivariate analyses. Results: The clinical pathological features of clinical stage at initial diagnosis, T stage, M stage, histological degree, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor-2 (HER-2) status and molecular subtype were significantly different between two groups (all P < 0.05). The median ages at recurrence/metastasis of patients with breast ILC and IDC were 50 years (range: 28-73) and 51 years (range: 27-69), respectively. The differences in the number of first metastatic sites, lymph node metastasis, visceral metastasis, lung metastasis and bone metastasis were statistically significant between two groups (all P < 0.05). The median progression-free survivals of patients with breast ILC and IDC were 14 months (range: 2-62) and 11 months (range: 1-89), respectively (P = 0.121). The median metastasesoverall survivals (M-OS) of patients with ILC and IDC were 42 months (range: 5-78) and 44 months ((range: 1-110), respectively (P = 0.392). Multivariate analysis revealed that PR status, age at recurrence or metastasis and treatment of bone metastases were the independent predictors of survival in patients with advanced breast ILC (all P < 0.05). The molecular subtype, the number of first metastatic sites and pleural effusion were the independent prognostic factors in patients with breast IDC (all P < 0.05). Conclusion: Patients with advanced breast ILC have unique clinicopathological, recurrent/metastatic and prognostic features. It is necessary to reveal the definitive features of ILC and develop new personalized precision therapies.
